Onchilles Pharma to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

February 23, 2026

SAN DIEGO, February 23, 2026 – Onchilles Pharma, a private biotech company pioneering next-generation cytotoxic therapeutics that leverage the ELANE pathway, today announced that management will present and be available for 1-on-1 meetings at the Oppenheimer 36th Annual Healthcare Life Sciences Conference.

Presentation Details:

Date: Thursday, February 26, 2026

Time: 2:00 p.m. to 2:30 p.m. ET

Format: Virtual presentation

For more details or to schedule a meeting, please contact info@onchillespharma.com.  

About Onchilles Therapeutic Programs Targeting the ELANE Pathway

At the core of this approach is the ELANE pathway, a unique cancer-selective killing mechanism that leverages a vulnerability shared by many cancer cell types: elevated histone H1 levels. By targeting the ELANE pathway and inducing immunogenic cancer cell death, N17350 and NEU-002 are designed to rapidly eliminate tumors while mobilizing an adaptive immune response, offering the potential for sustained anti-tumor immunity. N17350 and NEU-002 offer a unique approach to treating cancer regardless of their genetic makeup, anatomical origin, or immune status, positioning them as potential game-changers in cancer therapy.

About Onchilles Pharma

Onchilles Pharma is a global drug discovery and development company pioneering first-in-class cytotoxic therapies designed to selectively kill cancer cells while preserving and activating immune function. By harnessing the ELANE pathway, these next-generation therapeutics are designed to deliver potent and selective tumor cell destruction, overcoming the limitations of traditional chemotherapy and immunotherapy. The company’s pipeline includes N17350, a tumor-directed lead candidate in first-in-human studies, and the NEU-002 program for systemic delivery which extends the reach of N17350 to address all solid tumors. For more information, visit www.onchillespharma.com. 

Contacts

Company: Peter Haberz, Ph.D., Vice President, Corporate Development, info@onchillespharma.com

Media: Jessica Yingling, Ph.D., Little Dog Communications Inc., jessica@litldog.com